Category: News

Ossium featured in NYSE Floor Talk

Ossium CEO Kevin Caldwell recently visited the NYSE and was interviewed on the trading floor.

In Kevin’s conversation with the NYSE’s Judy Shaw, they discussed unmet needs and inequities in the current system for finding bone marrow donors and how Ossium is solving those problems by transforming the process for bone marrow donor acquisition. As Kevin summarizes, “the basic idea is to take these cell therapies that today are both very slow and consequently also very expensive and turn them into a scalable procedure that could ultimately benefit tens of thousands of patients around the world every year.”

The interview wraps up with a discussion of the potential for Ossium to utilize its unique bone marrow banking platform to improve treatments in other fields of medicine.

Check out the full interview below.

Ossium Health Named to Forbes’ List of America’s Best Startup Employers

We’re proud to announce that we’ve been named to Forbes’ prestigious list of America’s Best Startup Employers! This recognition places us among the top 500 U.S. startups based on employee satisfaction, reputation, and company growth.

This award reflects our dedication to fostering a work environment that attracts and retains exceptional talent. Ossium employees are driven by the profound impact our work has on individuals battling life-threatening blood and immune diseases. Our team’s unwavering dedication fuels our progress towards our company mission: improving the health, vitality, and longevity of human beings through bioengineering.

See Ossium’s appearance on Forbes’ list of America’s Best Startup Employers here.

Lauren Barnes Joins Ossium Health’s Board of Directors

We’re thrilled to announce that we’ve elected Lauren Barnes to our Board of Directors. Barnes is a leading expert in healthcare product commercialization, pricing, reimbursement, market access, and managed markets for products spanning various market segments. This addition significantly bolsters our capacity to drive growth and deliver life-changing solutions for patients suffering from hematologic diseases, organ transplant rejection, and musculoskeletal defects.

“We’re delighted to welcome Lauren as the newest addition to the Ossium Board,” said Kevin Caldwell, Ossium’s CEO, Co-Founder & President. “Lauren brings a fresh perspective to our shared passion for advancing the health, vitality, and longevity of human beings. I’m confident that her valuable insights and expertise will meaningfully help Ossium as the company continues to grow and positively impact more patients.”

Barnes’ appointment underscores our dedication to assembling a world-class Board of Directors equipped with diverse perspectives and proven expertise. Her expertise in commercialization and market access strategy at biopharmaceutical companies in various stages of development complements the expertise of the incumbent board members and will further propel us toward our goals.

Read the press release here.

Lauren Barnes is Ossium’s newest board member

Ossium Presents at Meeting on the Mesa

At our second appearance at the Cell & Gene Meeting on the Mesa, hosted by the Alliance for Regenerative Medicine, Ossium CEO Kevin Caldwell presented an update on our work over the past year and outlined our vision for the future of bone marrow transplantation. 

In the presentation, Kevin explained how we’re transforming the bone marrow donation process from a service into a product. With our bone marrow bank, patients have access to a high-quality, optimally-dosed, and fully-characterized graft, eliminating the months-long wait and uncertainty associated with searching for an unrelated living donor. Our vision is to enhance the existing bone marrow registry, enabling physicians to quickly search for a matched donor in a single, comprehensive registry. Ossium’s unique advantage allows physicians to expedite patients’ treatment by immediately ordering the graft once a matched donor is found. This reimagined system allows transplants to be performed in a matter of days instead of months, improving outcomes for patients whose conditions require immediate treatment.

Kevin also provided a brief update on our GVHD study and how it fits into Ossium’s goals: “Our goal is to increase the number of procedures that can be done by making them fundamentally safer.” He described how this complements Ossium’s efforts “to increase the speed, efficiency, and quality with which [bone marrow transplants] can be done by making the bone marrow itself far easier to get.”

Lastly, Kevin introduced our newest product, OssiGraft™, a viable bone matrix allograft. He explained how working with tissue from donors that have already been screened to meet organ donation and bone marrow donation requirements results in the highest quality bone graft on the market today.

Watch the full presentation below.

Ossium Presents at Organ Donation Congress

Kevin Caldwell, Ossium’s CEO, Co-Founder & President, recently presented an update on our bone marrow transplant study at the 2023 Congress of the International Society for Organ Donation and Procurement. As Kevin explains in the presentation, the initiation of this clinical study is an important step toward our goal of dramatically expanding access to life-saving bone marrow transplants for blood cancer patients and enabling these procedures to be used far more broadly in the future. With our bone marrow available on-demand, patients can bypass the lengthy and uncertain process of identifying a living donor. Furthermore, patients will benefit from improved treatment outcomes due to the ability to obtain an optimized dose specific to their size and condition with lower T-cell counts.

“Our goal is to show that there’s no tradeoff between increasing the accessibility of a treatment, increasing the affordability of a treatment, and increasing the quality of a treatment. We really are shooting for all three,” summarized Kevin.

The presentation also includes an overview of Ossium’s studies of Graft-versus-Host Disease treatment and solid organ transplant tolerance induction.

Watch the full presentation below.

Healio Article Highlights PRESERVE I Study

The first-in-human study of Ossium’s bone marrow (PRESERVE I) was recently featured in an article published by Healio, a major medical news source for healthcare professionals. The article includes an interview with Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, and Erin Leckrone, Vice President of Clinical Trials at the National Marrow Donor Program (NMDP)/Be The Match. In the interview, Caldwell and Leckrone outline the goals of the Ossium-NMDP/Be The Match partnership, including how the organizations plan to work together to fill unmet needs in hematopoietic cell transplantation. “We are dedicated to partnering with organizations like Ossium, who have innovative products that could potentially fill the unmet needs in transplantation,” said Leckrone. Leckrone goes on to explain how the clinical study data will be leveraged to drive the integration of Ossium’s bone marrow into the NMDP/Be The Match registry, facilitating seamless access for transplant centers in the future. 

Read the full article and interview here.

Ossium Health Featured in Nasdaq Live from MarketSite

Kevin Caldwell, CEO, Co-Founder & President of Ossium Health, recently sat down for an interview with Nasdaq’s Kristina Ayanian at their New York headquarters. In the interview, Kevin explained how Ossium is leveraging its organ donor-derived bone marrow platform to improve the accessibility and quality of leukemia treatments today and develop innovative therapies for organ rejection and orthopedic applications tomorrow.

See the full interview below.

Ossium Health® and Be The Match® Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency

Ossium Health, an innovative bioengineering company, is accelerating its mission to revolutionize the field of bone marrow transplantation through a new partnership with the National Marrow Donor Program (NMDP)/Be The Match, which manages the most diverse registry of blood stem cell donors and cord blood units in the world. This collaboration will enable blood cancer patients to access transplantable units of bone marrow from deceased donors through clinical trials, providing a much-needed complement to today’s living donor model.

Read the full story here.